Trial Review

Please note that the ANZCTR website will be unavailable from 1:00pm until 2:00pm (AEST) on Thursday 10th of April for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.


The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01116206




Registration number
NCT01116206
Ethics application status
Date submitted
3/05/2010
Date registered
4/05/2010
Date last updated
21/03/2017

Titles & IDs
Public title
An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation
Scientific title
A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prucalopride (Resolor) Tablets in Participants With Chronic Constipation
Secondary ID [1] 0 0
PRUCRC3001
Secondary ID [2] 0 0
CR017173
Universal Trial Number (UTN)
Trial acronym
Resolor
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Constipation 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Prucalopride
Treatment: Drugs - Placebo

Experimental: Prucalopride - prucalopride 2- milligram (mg), orally once daily for 12 weeks

Placebo comparator: Placebo - Matching placebo, orally once daily for 12 weeks


Treatment: Drugs: Prucalopride
2 mg tablet, orally once daily, for 12 weeks

Treatment: Drugs: Placebo
1 tablet, orally once dailyfor 12 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an Average of 3 or More Spontaneous Complete Bowel Movements (SCBMs)
Assessment method [1] 0 0
Percentage of responders (responders: participants with an average of 3 or more SCBMs per week) will be assessed during 12-week double-blind treatment phase (total treatment duration). SCBM is defined as a Spontaneous Bowel Movement (SBM) associated with a sense of complete evacuation. SBM is defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository used on either the calendar day of the BM or the calendar day before the BM. The total number of SBMs associated with a feeling of complete evacuation will be summed and divided by 12. Average weekly frequency of SCBMs will be calculated as number of SCBMs in treatment phase multiplied by 7 divided by total number of evaluable days in treatment phase.
Timepoint [1] 0 0
Week 1 to 12
Secondary outcome [1] 0 0
Percentage of Participants With an Average of 3 or More SCBMs During the First 4 Weeks
Assessment method [1] 0 0
Percentage of responders (participants with an average of 3 or more SCBMs per week) will be assessed during first 4 weeks of 12-week double-blind treatment phase (total treatment duration). SCBM will be defined as a Spontaneous Bowel Movement (SBM) associated with a sense of complete evacuation. SBM is defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository used on either the calendar day of the BM or the calendar day before the BM. Average weekly frequency of SCBMs will be calculated as number of SCBMs in Week 1 to 4 multiplied by 7 divided by total number of evaluable days in Week 1 to 4.
Timepoint [1] 0 0
Week 1 to 4
Secondary outcome [2] 0 0
Percentage of Participants With an Average Increase of 1 or More Bowel Movements (BMs)
Assessment method [2] 0 0
Percentage of participants with an average increase of 1 or more SCBMs per week as compared to the run-in phase (that is screening phase at Week Minus 2) will be assessed. SCBM is defined as SBM that is associated with a sense of complete evacuation. SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM. Average weekly frequencies will be calculated as number of SCBMs in interval multiplied by 7 divided by total number of evaluable days in interval.
Timepoint [2] 0 0
Week 1 to 12
Secondary outcome [3] 0 0
Percentage of Participants With an Average of 3 or More SCBMs During Weeks 5 to 8 and 9 to 12
Assessment method [3] 0 0
Percentage of participants with an average increase of 3 or more SCBMs per week will be assessed. SCBM is defined as SBM that is associated with a sense of complete evacuation. SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM. Average weekly frequencies will be calculated as number of SCBMs in interval multiplied by 7 and divided by total number of evaluable days in interval.
Timepoint [3] 0 0
Week 5 to Week 8 and Week 9 to Week 12
Secondary outcome [4] 0 0
Average Number of SCBMs
Assessment method [4] 0 0
An increase in the average number of SCBMs per week will be assessed during Weeks 1 to 12. SCBM will be defined as a SBM that is associated with a sense of complete evacuation. SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM. Average weekly frequencies will be calculated as (number of SCBMs in interval \* 7) / number of evaluable days in interval.
Timepoint [4] 0 0
Week 1 to 12
Secondary outcome [5] 0 0
Average Number of Spontaneous Bowel Movements (SBMs)
Assessment method [5] 0 0
Average number of SBMs is assessed. SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM. Average weekly frequencies will be calculated as (number of SBMs in interval \* 7) / number of evaluable days in interval.
Timepoint [5] 0 0
Week 1 to 12
Secondary outcome [6] 0 0
Average Number of all Bowel Movements (BMs)
Assessment method [6] 0 0
Average number of BMs will be assessed.BMs are spontaneous discharge of waste matterfrom the large intestine. Average weekly frequencies will be calculated as (number of BMs in interval \* 7) / number of evaluable days in interval.
Timepoint [6] 0 0
Week 1 to 12
Secondary outcome [7] 0 0
Time-to-First SCBM and Time-to-First Week With 3 or More SCBMs After the First Dose of the Study Drug
Assessment method [7] 0 0
SCBM is defined as a SBM that is associated with a sense of complete evacuation. SBM is defined as a bowel movement BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM. Average weekly frequencies will be calculated as (number of SCBMs in interval \* 7) / number of evaluable days in interval.
Timepoint [7] 0 0
Week 1 to 12
Secondary outcome [8] 0 0
Average Number of Bisacodyl Tablets
Assessment method [8] 0 0
Average number of bisacodyl tablets taken is determined. Bisacodyl 5, 10, or 15 milligram (mg) is used as rescue medication. Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation. Average weekly frequencies will be calculated as (number of bisacodyl tablets in interval \* 7) / number of evaluable days in interval.
Timepoint [8] 0 0
Week 1 to 12
Secondary outcome [9] 0 0
Percentage of Participants With Zero, Less Than (<) 2 and Greater Than and Equal to (>=) 2 Tablets of Bisacodyl Taken
Assessment method [9] 0 0
Average number of bisacodyl tablets taken will be determined during 12-week double-blind treatment phase. Bisacodyl 5, 10, or 15 milligram (mg) will be used as rescue medication. Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation. Average weekly frequencies will be calculated as (number of bisacodyl tablets in interval \* 7) / number of evaluable days in interval.
Timepoint [9] 0 0
Week 1 to 12
Secondary outcome [10] 0 0
Percentage of BMs With Normal Consistency
Assessment method [10] 0 0
Percentage of BM with normal consistency for each participant will be calculated by dividing number of BMs with normal consistency with total number of BMs in that participant multiplied by 100. Average of percentage of BM with normal consisitency for all participants have been reported. The consistency of each BM will be assessed using the 7-point Bristol Stool Scale: score ranging from 1 to 7,wherein 1=stool is separate hard lumps, like nuts (hard to pass); and 7=watery, no solid pieces, entirely liquid (passed easily). Score 3 and 4 indicates normal consistency.
Timepoint [10] 0 0
Week 1 to 12
Secondary outcome [11] 0 0
Percentage of BMs With Less Straining
Assessment method [11] 0 0
Percentage of BM with less straining for each participant will be calculated by dividing number of BMs with less straining with total number of BMs in that participant multiplied by 100. Average of percentage of BM with less straining for all participants will be reported. Degree of straining is measured on a 5-point scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. Less straining indicates none or mild degree of straining.
Timepoint [11] 0 0
Week 1 to 12
Secondary outcome [12] 0 0
Percentage of BMs with a Sensation of Complete Evacuation
Assessment method [12] 0 0
Percentage of BM with a sensation of complete evacuation for each participant will be calculated by dividing number of BMs with a sensation of complete evacuation with total number of BMs in that participant multiplied by 100. Average of percentage of BM with a sensation of complete evacuation for all participants will be reported. Percentage of BMs with a sensation of complete evacuation will be calculated as (number of BMs with a sensation of complete evacuation in interval / \[number of SCBMs or BMs with non - missing scores in interval\] \* 100%).
Timepoint [12] 0 0
Week 1 to 12
Secondary outcome [13] 0 0
Participants Global Assessment on Consistency of Stool
Assessment method [13] 0 0
Participants Global Assessment on consistency of stool will be assessed with Types 1-2=constipation,Types 3-4= ideal stools and Types 5-7=further tending towards diarrhea or urgency based on Bristol Stool Scale. Bristol Stool Scale:1=stool is separate hard lumps, like nuts (hard to pass);2=stool is sausage-shaped but lumpy; 3=stool is like a sausage but with cracks on its surface; 4=stool is like a sausage or snake, smooth and soft; 5=stool is soft blobs with clear-cut edges (passed easily);6=fluffy pieces with ragged edges, mushy stool;7=watery, no solid pieces, entirely liquid (passed easily).
Timepoint [13] 0 0
Week 2, 4, 8 and 12
Secondary outcome [14] 0 0
Participants Global Assessment on Severity of Constipation
Assessment method [14] 0 0
Participants Global Assessmentof severity of constipation will be assessed using a 5-point scale ranging from 0 to 4: 0=absent (no constipation); 1=mild constipation; 2=moderate constipation; 3=severe constipation; 4=very severe constipation.
Timepoint [14] 0 0
Week 2, Week 4, Week 8 and Week 12
Secondary outcome [15] 0 0
Participants Global Assessment on Efficacy of Treatment
Assessment method [15] 0 0
Participants global assessment on efficacy of treatment was assessed using a 5-point scale ranging from 0 to 5: 0=not at all effective; 1=a little bit effective; 2=moderately effective; 3=quite a bit effective; 4=extremely effective.
Timepoint [15] 0 0
Week 2, Week 4, Week 8, and Week 12
Secondary outcome [16] 0 0
Investigator's Global Assessment on Efficacy of Treatment
Assessment method [16] 0 0
Investigator's Global Assessment on efficacy of treatment will be assessed using rating on a 5-point scale: 0=not at all effective; 1=a little bit effective; 2=moderately effective; 3=quite a bit effective; 4=extremely effective
Timepoint [16] 0 0
Week 4 and 12
Secondary outcome [17] 0 0
Change From Baseline in Patient Assessment of Constipation-Symptom Questionnaire (PAC-SYM) Total Score at Week 2, 4, 8 and 12
Assessment method [17] 0 0
The PAC-SYM is a 12-item participant self-administered instrument that measures the severity of constipation-related symptoms. Items are rated on a 5-point Likert scale, where 0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe. The PAC-SYM contains 3 subscales: stool symptoms (5 items), abdominal symptoms (4 items) and rectal symptoms (3 items)
Timepoint [17] 0 0
Baseline, Week 2, 4, 8, and 12
Secondary outcome [18] 0 0
Change From Baseline in the PAC-SYM Subscale Scores at Week 2, 4, 8 and 12
Assessment method [18] 0 0
The PAC-SYM is comprised of the following 3 subscales: Stool symptoms (5 items): bowel movements that require straining or squeezing, bowel movements that are too hard, bowel movements that are too small, bowel movements that result in a sensation of incomplete evacuation, the feeling of having to pass a bowel movement but couldn't (false alarm); Abdominal symptoms (4 items):abdominal discomfort, abdominal pain, abdominal cramping, abdominal bloating; Rectal symptoms (3 items): painful bowel movements, rectal burning, bleeding or tearing during or after a bowel movement.
Timepoint [18] 0 0
Baseline, Week 2, 4, 8, and 12
Secondary outcome [19] 0 0
Percentage of Participant's who Rated Study Drug effectiveness
Assessment method [19] 0 0
The percentage of participants who rated the study treatment with efficacy score of 3=quite a bit to 4=extremely effective on global evaluation of efficacy of treatment was determined.
Timepoint [19] 0 0
Week 2, Week 4, Week 8 and Week 12
Secondary outcome [20] 0 0
Percentage of Participants With PAC SYM Score
Assessment method [20] 0 0
Percentage of participants with an improvement of greater than or equal to 1 point on the PAC SYM score will be determined. The PAC-SYM is a 12-item participant self-administered instrument that measures the severity of constipation-related symptoms. Items are rated on a 5-point Likert scale, where 0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe. The PAC-SYM contains 3 subscales: stool symptoms (5 items), abdominal symptoms (4 items) and rectal symptoms (3 items).
Timepoint [20] 0 0
Weeks 2, 4, 8, and 12

Eligibility
Key inclusion criteria
* History of chronic constipation, defined as on average, 2 or fewer spontaneous bowel movements (SBMs) per week and 1 or more of the following for at least a quarter of the time for the last 3 months, while symptom onset was more than 6 months before the screening visit: in more than 25 percent (%) of BMs, participants had very hard (little balls) and/or hard stools, sensation of incomplete evacuation, straining at defecation (making a bowel movement), sensation of ano-rectal obstruction or blockade, and/or need for digital manipulation to facilitate evacuation
* Participants who were considered as constipated (who never had SBMs)
* Participant's constipation is functional
* Participants with the diagnosis of irritable bowel syndrome (bowel disorder in which there is pain and diarrhea or constipation) with constipation and with no other organic diseases can potentially be included depending on the decision of the investigator
* Female participants must be postmenopausal (for at least 1 year) or surgically sterile or practicing a highly effective method of birth control
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Secondary to other diseases/conditions (endocrine disorders, metabolic disorders or neurologic disorders or drug-induced or suspected organic disorders of the large bowel, i.e., obstruction, carcinoma (type of cancer), or inflammatory bowel disease)
* - Participants Using or intending to use disallowed medications that may influence the bowel habit during the study
* Participants with severe (very serious, life threatening) and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer (abnormal tissue that grows and spreads in the body until it kills) or acquired immune deficiency syndrome (AIDS: illness that results in decreased ability of the body to protect itself from other illnesses; development of the disease or conditions associated with the disease results from Human Immunodeficiency Virus [HIV]), or other gastrointestinal or endocrine disorders
* Participants with impaired renal function, that is, serum creatinine greater than 2 milligram per deciliter (greater than 180 micro mole per liter)
* Participants with clinically significant abnormalities of hematology, urinalysis, or blood chemistry

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2011
Sample size
Target
Accrual to date
Final
507
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Box Hill
Recruitment hospital [3] 0 0
- Kingswood
Recruitment hospital [4] 0 0
- Kogarah
Recruitment hospital [5] 0 0
- Newcastle
Recruitment hospital [6] 0 0
- Parkville
Recruitment hospital [7] 0 0
- Prahran
Recruitment hospital [8] 0 0
- Sydney
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Box Hill
Recruitment postcode(s) [3] 0 0
- Kingswood
Recruitment postcode(s) [4] 0 0
- Kogarah
Recruitment postcode(s) [5] 0 0
- Newcastle
Recruitment postcode(s) [6] 0 0
- Parkville
Recruitment postcode(s) [7] 0 0
- Prahran
Recruitment postcode(s) [8] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
China
State/province [1] 0 0
Beijing
Country [2] 0 0
China
State/province [2] 0 0
Chongqing
Country [3] 0 0
China
State/province [3] 0 0
Guangzhou
Country [4] 0 0
China
State/province [4] 0 0
Hangzhou
Country [5] 0 0
China
State/province [5] 0 0
Hefei
Country [6] 0 0
China
State/province [6] 0 0
Jinan
Country [7] 0 0
China
State/province [7] 0 0
Nanjing
Country [8] 0 0
China
State/province [8] 0 0
Shanghai
Country [9] 0 0
China
State/province [9] 0 0
Wuhan
Country [10] 0 0
China
State/province [10] 0 0
Xian
Country [11] 0 0
Korea, Republic of
State/province [11] 0 0
Busan
Country [12] 0 0
Korea, Republic of
State/province [12] 0 0
Dae-Gu
Country [13] 0 0
Korea, Republic of
State/province [13] 0 0
Deajun
Country [14] 0 0
Korea, Republic of
State/province [14] 0 0
Gwangju-Si
Country [15] 0 0
Korea, Republic of
State/province [15] 0 0
Iksan
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Seoul
Country [17] 0 0
Taiwan
State/province [17] 0 0
Taipei
Country [18] 0 0
Thailand
State/province [18] 0 0
Bamgkok
Country [19] 0 0
Thailand
State/province [19] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C Clinical Trial
Address 0 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01116206